Biotech News

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

Oric Pharmaceuticals, Inc. (ORIC)Oric Pharmaceuticals, Inc.2026-06-25 13:46 ESTClinical readout

Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported rinzimetostat data in post-abiraterone mCRPC supporting potential best-in-disease profile, including a

Open original release

Related news

ORICOric Pharmaceuticals, Inc.2026-06-25 13:46 EST

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORICOric Pharmaceuticals, Inc.2026-06-25 13:46 EST

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates

ORICOric Pharmaceuticals, Inc.2026-06-25 13:46 EST

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

ORICOric Pharmaceuticals, Inc.2026-06-25 13:46 EST

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

ORICOric Pharmaceuticals, Inc.2026-06-25 13:46 EST

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

ORICOric Pharmaceuticals, Inc.2026-06-25 13:46 EST

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORICOric Pharmaceuticals, Inc.2026-06-25 13:46 EST

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

JAGXJaguar Health2026-06-25 13:46 EST

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

View all latest news

Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ORICOric Pharmaceuticals, Inc.2026-06-26 09:54 EST

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORICOric Pharmaceuticals, Inc.2026-06-26 09:54 EST

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates

ORICOric Pharmaceuticals, Inc.2026-06-26 09:54 EST

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

ORICOric Pharmaceuticals, Inc.2026-06-26 09:54 EST

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

ORICOric Pharmaceuticals, Inc.2026-06-26 09:54 EST

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States